Study #2022-0356
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered with Membrane Bound IL15 Plus Acetazolamide in Adult Patients with Metastatic Melanoma
MD Anderson Study Status
Not Accepting
Treatment Agent
OBX-115, Acetazolamide, Cyclophosphamide, Furosemide, Mesna, Fludarabine Phosphate
Description
To find the recommended dose of OBX-115 in combination with acetazolamide that can be given to patients with metastatic melanoma previously treated with immune checkpoint inhibitors.
Information and next steps
Disease:
Tumor, Metastatic Melanoma, Melanoma
Study phase:
I
Physician name:
Rodabe Amaria
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.